On 23 February 2004, orphan designation (EU/3/04/186) was granted by the European Commission to medac Gesellschaft fuer klinische Spezialpräparate mbH, Germany, for treosulfan for the conditioning treatment prior to haematopoietic progenitor cell transplantation.
Please note that this product (marketed as Trecondi) was withdrawn from the Community Register of designated orphan medicinal products by the European Commission in June 2019 at the time of the granting of a marketing authorisation.
|Disease / condition||
Conditioning treatment prior to haematopoietic-progenitor-cell transplantation
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.